---
title: "Darzalex (daratumumab) in multiple myeloma: Guidelines questions"
description: "Guidelines questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Do NCCN guidelines recommend Darzalex (daratumumab) for newly diagnosed myeloma? 1 question quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Guidelines questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Guidelines

<a id="darzalex-nccn-recommendations"></a>

### Do NCCN guidelines recommend Darzalex (daratumumab) for newly diagnosed myeloma?

Applies to: Newly diagnosed multiple myeloma, transplant-eligible and transplant-ineligible

> “The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) may contain data, conclusions, and recommendations that do not conform to the FDA-approved labeling for the products discussed herein and have not been evaluated by the FDA. No conclusions should be drawn. Daratumumab (DARZALEX<sup>®</sup>) and daratumumab and hyaluronidase-fihj (DARZALEX FASPRO<sup>®</sup>) should be used only as specified in the Prescribing Information.”

Source: [DARZALEX: CEPHEUS Study Design, captured 2026-11-12](https://www.darzalexhcp.com/quad/cepheus/study-design/#:~:text=The%20NCCN%20Clinical%20Practice%20Guidelines,specified%20in%20the%20Prescribing%20Information.)

> “Daratumumab<sup>‡</sup> (D) in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d) is recommended by the NCCN Guidelines<sup>®</sup> as a Category 1 preferred therapeutic option for patients with newly diagnosed multiple myeloma who are ineligible for transplant<sup>§</sup> (for patients <80 years old who are not frail).<sup>6</sup>”

Source: [DARZALEX: CEPHEUS Study Design, captured 2026-11-12](https://www.darzalexhcp.com/quad/cepheus/study-design/#:~:text=%28D%29%20in%20combination%20with%20bortezomib,years%20old%20who%20are%20not)

> “<sup>§</sup>If hematopoietic cell transplantation (HCT)-deferred or not indicated.”

Source: [DARZALEX: CEPHEUS Study Design, captured 2026-11-12](https://www.darzalexhcp.com/quad/cepheus/study-design/#:~:text=hematopoietic%20cell%20transplantation%20%28HCT%29%2Ddeferred%20or%20not%20indicated.)

> “Daratumumab<sup>†</sup> (D) in combination with lenalidomide (R) and dexamethasone (d) is recommended by the NCCN Guidelines<sup>®</sup> as a Category 1 preferred therapeutic option for patients with newly diagnosed multiple myeloma when hematopoietic stem cell transplant is deferred or not indicated.<sup>7</sup>”

Source: [DARZALEX: MAIA Study Design, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/study-design/#:~:text=%28D%29%20in%20combination%20with%20lenalidomide,transplant%20is%20deferred%20or%20not)

> “Safety and effectiveness of DRd in the transplant-deferred patient population has not been evaluated in a phase 3 study and has not been established.”

Source: [DARZALEX: MAIA Study Design, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/study-design/#:~:text=Safety%20and%20effectiveness%20of%20DRd,and%20has%20not%20been%20established.)

> “Daratumumab* and hyaluronidase-fihj (D) in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d) is recommended by the NCCN Guidelines<sup>®</sup> as a Category 1 preferred therapeutic option for patients with newly diagnosed multiple myeloma who are eligible for hematopoietic stem cell transplant.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Daratumumab%2A%20and%20hyaluronidase%2Dfihj%20%28D%29%20in,for%20hematopoietic%20stem%20cell%20transplant.)

Note: The pages cite NCCN Guidelines for Multiple Myeloma V.5.2026.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
